2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Amylases

Amylases

Amylases are crucial enzymes which hydrolyze internal glycosidic linkages in starch and produce as primary products dextrins and oligosaccharides. Amylases are classified into α-amylase, β-amylase, and glucoamylase based on their three-dimensional structures, reaction mechanisms, and amino acid sequences. Amylases have innumerable applications in clinical, medical, and analytical chemistries as well as in food, detergent, textile, brewing, and distilling industries.

Amylases Related Products (96):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-143268
    HPA-IN-1
    		Inhibitor
    HPA-IN-1 (Compound 1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC50 values of 12.0 μM and 410.4 μM against HPA and α-glucosidase, respectively.
    HPA-IN-1
  • HY-N11844
    Quercetin 3-(6″-caffeoylsophoroside)
    		Inhibitor
    Quercetin 3-(6″-caffeoylsophoroside) is an orally active α-amylase inhibitor, with an IC50 of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research.
    Quercetin 3-(6″-caffeoylsophoroside)
  • HY-N17215
    3,4,6-Tri-O-galloyl-D-glucose
    		Inhibitor
    3,4,6-Tri-O-galloyl-D-glucose (3,4,6-Trigalloylglucose) is an α-amylase (porcine α-amylase IC50 = 334.6 μM; Ki = 307.5 μM) and α-glucosidase (yeast α-glucosidase IC50 = 46.5 μM; Ki = 39.9 μM) mixed type inhibitor. 3,4,6-Tri-O-galloyl-D-glucose exhibits free radical scavenging ability, ferric-reducing power, and antioxidant activity. 3,4,6-Tri-O-galloyl-D-glucose can be used for the research of diabetes.
    3,4,6-Tri-O-galloyl-D-glucose
  • HY-154972
    α-Amylase/α-Glucosidase-IN-3
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC50s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus.
    α-Amylase/α-Glucosidase-IN-3
  • HY-161429
    Antidiabetic agent 5
    		Inhibitor
    Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC50 values of 3.91，8.89 μM，respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes.
    Antidiabetic agent 5
  • HY-N17294
    Dendromoniliside D
    		Inhibitor
    Dendromoniliside D is a sesquiterpene glycoside. Dendromoniliside D can be isolated from D. nobile. Dendromoniliside D inhibits α-amylase. Dendromoniliside D can be used in the research of liver cancer, lung cancer, and breast cancer.
    Dendromoniliside D
  • HY-178363
    α-Amylase-IN-13
    		Inhibitor
    α-Amylase-IN-13 is an orally active, selective, brain-penetrant α-amylase inhibitor (IC50 = 0.71 μM). α-Amylase-IN-13 inhibits α-amylase through a mixed type of inhibition mechanism. α-Amylase-IN-13 leads to a significant reduction in blood glucose level in diabetic rats. α-Amylase-IN-13 causes significant histopathological improvements in the kidney, liver, and pancreas. α-Amylase-IN-13 can be used for the study of diabetic complications.
    α-Amylase-IN-13
  • HY-N16656
    Ladyginoside A
    		Inhibitor
    Ladyginoside A is a triterpenoid saponin found in the leaves of Polyscias fruticosa (L.) Harms. Ladyginoside A has inhibitory activities against α-amylase and α-glucosidase, and can regulate carbohydrate metabolism. Ladyginoside A also exhibits potential anti-inflammatory and mast cell stabilizing effects. Ladyginoside A can be used for the researches of inflammation and metabolic disease, such as diabetes.
    Ladyginoside A
  • HY-N0668R
    Rubusoside (Standard)
    		Inhibitor
    Rubusoside (Standard) is the analytical standard of Rubusoside. This product is intended for research and analytical applications. Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
    Rubusoside (Standard)
  • HY-N14506
    Gibbestatin B
    		Inhibitor
    Gibbestatin B inhibits the expression of α-amylase induced by gibberellin in De-embryoned rice and barley (IC50 is 25-50 ppm), and has no anti-bacterial, anti-yeast and anti-fungal effects at 100 ppm.
    Gibbestatin B
  • HY-N2376R
    Chrysin-7-O-glucuronide (Standard)
    		Inhibitor
    Chrysin-7-O-glucuronide (Standard) is the analytical standard of Chrysin-7-O-glucuronide (Hy-N2376). This product is intended for research and analytical applications. Chrysin-7-O-glucuronide is a flavonoid found in Scutellaria baicalensis. Chrysin-7-O-glucuronide inhibits α-glucosidase and α-amylase with IC50 values of 612.13 and 980.73 μg/mL. Chrysin-7-O-glucuronide suppresses NF-κB signaling activity. Chrysin-7-O-glucuronide scavenges free radicals, acts as a tight junction protector, and mitigates intestinal mucosal barrier injury. Chrysin-7-O-glucuronide can be used for the research of type 2 diabetes and severe acute pancreatitis-induced intestinal mucosal barrier injury.
    Chrysin-7-O-glucuronide (Standard)
  • HY-113159A
    Docosapentaenoic acid (22n-3) sodium
    		Inhibitor
    Docosapentaenoic acid (22n-3) sodium is a component of phospholipids. Docosapentaenoic acid 22n-3 sodium has inhibitory activity against α-amylase and α-glucosidase, with IC50s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 sodium increases cell vitality. Docosapentaenoic acid 22n-3 sodium has a weak anti-inflammatory effect.
    Docosapentaenoic acid (22n-3) sodium
  • HY-170796
    α-Amylase-IN-11
    		Inhibitor
    α-Amylase-IN-11 (compound C5f) is an α-Amylase inhibitor (IC50=0.56 μM) that can reduce the sugar level in vivo. α-Amylase-IN-11 has a moderate inhibitory effect on α-glucosidase (α-glucosidase), with IC50=11.03 μM. α-Amylase-IN-11 can significantly reduce the glucose concentration in a mouse model and has the potential for use in diabetes research.
    α-Amylase-IN-11
  • HY-170548
    α-Amylase-IN-10
    		Inhibitor
    α-Amylase-IN-10 (Compound 15n) is an inhibitor for α-Amylase with an IC50 of 5.00 µM. α-Amylase-IN-10 can be used for research of type 2 diabetes mellitus.
    α-Amylase-IN-10
  • HY-162635
    α-Amylase/α-Glucosidase-IN-14
    		Inhibitor
    α-Amylase/α-Glucosidase-IN-14 (compound 6E) is an oral bioactive inhibitor of α-amylase and α-glucosidase, with the IC50s of 45.53 μM and 27.73 μM, respectively.
    α-Amylase/α-Glucosidase-IN-14
  • HY-161782
    α-Amylase-IN-7
    		Inhibitor
    α-Amylase-IN-7 (Compound 6e) is an inhibitor for α-Amylase with an IC50 of 40 μM. α-Amylase-IN-7 exhibits potential as an antidiabetic agent.
    α-Amylase-IN-7